Cationic platelet lysate compositions and related methods
US11951134B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 30, 2020 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Dec 1, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An acellular, anion-depleted platelet-derived peptide-rich composition comprising proteins, polypeptides and peptides <10 kDa in size, wherein the composition has anti-microbial and/or anti-inflammatory activity is disclosed. The composition can be substantially free of non-active and immunogenic factors. The composition can have a platelet-to-bacteria ratio ≥1000:1. The composition can comprise plasma at a range of ≥10% to ≤50% plasma, optionally about 10% plasma. Methods of using the composition are also disclosed. Also disclosed is a method for preparing an acellular platelet-derived peptide-rich composition having anti-microbial and/or anti-inflammatory activity, the method comprising: providing a starting material comprising platelet-rich plasma processed to contain ≥1,000,000 platelet/μL, ≤100 leukocytes/μL and ≤10 erythrocyte/μL in plasma; lysing and/or activating the starting material; contacting the starting material with an ion exchange matrix and/or a size exchange matrix; and isolating the acellular platelet-derived peptide-rich composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.